Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, Seute T, Durian M, Cull G, van der Poel MWM, Stevens WBC, Zijlstra JM, Brandsma D, Nijland M, Mason KD, Beeker A, Abrahamse-Testroote MCJ, van den Bent MJ, de Jong D, Doorduijn JK.
Bromberg JEC, et al. Among authors: van der poel mwm, van der holt b, van der meulen m, van den bent mj.
Neuro Oncol. 2024 Apr 5;26(4):724-734. doi: 10.1093/neuonc/noad224.
Neuro Oncol. 2024.
PMID: 38037691
Free PMC article.
Clinical Trial.